Publications
Download CSV
Download XLSX
Download TXT
Tables
2024 (331)
2023 (584)
2022 (723)
2021 (1399)
2020 (842)
All (3879)
Labels
Labels list
Labels table
Researchers
Subset
Documentation
About
Contact
Software
Login
Research Area: Drug discovery and repurposing of drugs
JSON
CSV
XLSX
TXT
Primary
: Shown in the list of current labels.
Year 2022
PubMed
DOI
Crossref
Probing effects of the SARS-CoV-2 E protein on membrane curvature and intracellular calcium.
Mehregan A, Pérez-Conesa S, Zhuang Y, ..., Ulens C,
Delemotte L
Biochim Biophys Acta Biomembr
1864
(10) 183994 [2022-10-01; online 2022-06-18]
Category: Biochemistry
Category: Health
Category: Imaging
Funder: KAW/SciLifeLab National COVID program
Funder: VR
Research Area: Drug discovery and repurposing of drugs
Type: Journal article
PubMed
DOI
Crossref
COVID-19 seroprevalence and clinical picture in Swedish pediatric oncology and hematology patients.
Sundberg E
, Hoffman T,
Nilsson A
, ...,
Harila-Saari A
, Palle J
Pediatr Blood Cancer
-
(-) e29773 [2022-05-25; online 2022-05-25]
Category: Biochemistry
Category: Health
Funder: KAW/SciLifeLab National COVID program
Research Area: Drug discovery and repurposing of drugs
Research Area: Pandemic preparedness
Type: Journal article
PubMed
DOI
Crossref
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
Marking U,
Havervall S
, Greilert-Norin N, ..., Åberg M, Thålin C
Vaccines
10
(3) 359 [2022-02-24; online 2022-02-24]
Category: Biochemistry
Category: Health
Funder: KAW/SciLifeLab National COVID program
Funder: VR
Research Area: Biobanks for COVID-19 research
Research Area: Drug discovery and repurposing of drugs
Research Area: High-throughput and high-content serology
Type: Journal article
PubMed
DOI
Crossref
Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses.
Luttens A
, Gullberg H, Abdurakhmanov E, ...,
Danielson UH
,
Carlsson J
J Am Chem Soc
-
(-) - [2022-02-10; online 2022-02-10]
Category: Biochemistry
Category: Drug Discovery
Category: Health
Funder: KAW/SciLifeLab National COVID program
Research Area: Drug discovery and repurposing of drugs
Research Area: Pandemic preparedness
Type: Journal article
PubMed
DOI
Crossref
SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection
Havervall S
,
Jernbom Falk A
,
Klingström J
, ...,
Nilsson P
, Thålin C
PLoS One
17
(1) e0262169 [2022-01-12; online 2022-01-12]
Category: Biochemistry
Category: Health
Funder: KAW/SciLifeLab National COVID program
Funder: VR
Research Area: Biobanks for COVID-19 research
Research Area: Drug discovery and repurposing of drugs
Research Area: High-throughput and high-content serology
Research Area: Host cell systems biology and targets
Type: Journal article
PubMed
DOI
Crossref
A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo.
Hanke L
,
Das H
, Sheward DJ, ...,
Murrell B
,
McInerney GM
Nat Commun
13
(1) 155 [2022-01-10; online 2022-01-10]
Category: Biochemistry
Category: Health
Funder: H2020
Funder: KAW/SciLifeLab National COVID program
Funder: VR
Research Area: Drug discovery and repurposing of drugs
Type: Journal article
PubMed
DOI
Crossref
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
Havervall S
,
Ng H
,
Jernbom Falk A
, ...,
Hober S
,
Thålin C
J Intern Med
291
(1) 72-80 [2022-01-00; online 2021-09-27]
Category: Biochemistry
Category: Health
Funder: KAW/SciLifeLab National COVID program
Research Area: Biobanks for COVID-19 research
Research Area: Drug discovery and repurposing of drugs
Research Area: High-throughput and high-content serology
Research Area: Host cell systems biology and targets
Research Area: Viral sequence evolution
Year 2021
DOI
Crossref
Influenza A H1N1–mediated pre-existing immunity to SARS-CoV-2 predicts COVID-19 outbreak dynamics
Almazán NM, Rahbar A, Carlsson M, ..., Sörensen B, Söderberg-Nauclér C
medRxiv
-
(-) - [2021-12-25; online 2021-12-25]
Category: Genomics & transcriptomics
Category: Health
Category: Omicron VoC
Funder: KAW/SciLifeLab National COVID program
Research Area: Drug discovery and repurposing of drugs
Research Area: High-throughput and high-content serology
Type: Preprint
PubMed
DOI
Crossref
Plasma Proteome Fingerprints Reveal Distinctiveness and Clinical Outcome of SARS-CoV-2 Infection.
Bauer W
, Weber M, Diehl-Wiesenecker E, ...,
Micke P
,
Kappert K
Viruses
13
(12) 2456 [2021-12-07; online 2021-12-07]
Category: Biochemistry
Category: Health
Funder: KAW/SciLifeLab National COVID program
Research Area: Drug discovery and repurposing of drugs
Type: Journal article
DOI
Crossref
Neutralization of VOCs including Delta one year post COVID-19 or vaccine
Havervall S, Marking U, Gordon M, ..., Hober S, Thålin C
MedRxiv
-
(-) - [2021-08-12; online 2021-08-12]
Category: Biochemistry
Category: Health
Category: Vaccines
Funder: KAW/SciLifeLab National COVID program
Research Area: Biobanks for COVID-19 research
Research Area: Drug discovery and repurposing of drugs
Research Area: High-throughput and high-content serology
Research Area: Host cell systems biology and targets
Type: Preprint
PubMed
DOI
Crossref
A phenomics approach for antiviral drug discovery.
Rietdijk J, Tampere M, Pettke A, ..., Puumalainen MR,
Carreras-Puigvert J
BMC Biol
19
(1) 156 [2021-08-02; online 2021-08-02]
Category: Biochemistry
Category: Drug Discovery
Funder: H2020
Funder: KAW/SciLifeLab National COVID program
Funder: VR
Research Area: Drug discovery and repurposing of drugs
Type: Journal article
PubMed
DOI
Crossref
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S
, Marking U, Greilert-Norin N, ..., Åberg M,
Thålin C
EBioMedicine
70
(-) 103523 [2021-08-00; online 2021-08-12]
Category: Drug Discovery
Category: Health
Funder: KAW/SciLifeLab National COVID program
Research Area: Biobanks for COVID-19 research
Research Area: Drug discovery and repurposing of drugs
Research Area: High-throughput and high-content serology
Research Area: Host cell systems biology and targets
Type: Journal article
Year 2020
PubMed
DOI
Crossref
Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders.
Marklund E, Leach S, Axelsson H, ..., Liljeqvist JÅ, Gisslén M
PLoS One
15
(10) e0241104 [2020-10-21; online 2020-10-21]
Category: Biochemistry
Category: Health
Funder: KAW/SciLifeLab National COVID program
Research Area: Biobanks for COVID-19 research
Research Area: Biomarkers and systems immunology
Research Area: Drug discovery and repurposing of drugs
Research Area: High-throughput and high-content serology
Type: Journal article
PubMed
DOI
Crossref
Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro
Akaberi D, Krambrich J, Ling J, ..., Lennerstrand J, Lundkvist Å
Redox Biology
37
(-) 101734 [2020-09-21; online 2020-09-21]
Category: Imaging
Category: Proteins
Funder: KAW/SciLifeLab National COVID program
Funder: VR
Research Area: Drug discovery and repurposing of drugs
Type: Journal article
PubMed
DOI
Crossref
Spatio-Temporal Mutational Profile Appearances of Swedish SARS-CoV-2 during the Early Pandemic.
Ling J, Hickman RA, Li J, ..., Lundkvist Å, Järhult JD
Viruses
12
(9) - [2020-09-14; online 2020-09-14]
Category: Biochemistry
Category: Health
Funder: KAW/SciLifeLab National COVID program
Funder: VR
Research Area: Drug discovery and repurposing of drugs
Type: Journal article
PubMed
DOI
Crossref
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention
Nasi A
,
McArdle S
, Gaudernack G, ..., Sjölin J,
Mangsbo S
Toxicology Reports
7
(-) 768-771 [2020-00-00; online 2020-00-00]
Funder: KAW/SciLifeLab National COVID program
Research Area: Drug discovery and repurposing of drugs
Type: Review
SciLifeLab Data Centre
Publications
9.5.1-pretest